Global Recombinant Humanized Collagen Market Growth 2025-2031
Description
The global Recombinant Humanized Collagen market size is predicted to grow from US$ 104 million in 2025 to US$ 2560 million in 2031; it is expected to grow at a CAGR of 70.6% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant humanized collagen refers to the introduction of collagen sequences encoded by human genes into cells for expression and production through gene recombination technology to obtain proteins with the same or similar structural and biological characteristics as natural collagen. Recombinant humanized collagen has many advantages, such as controllable production process, high purity, non-infectiousness, etc. It has a wide range of application prospects in medicine, biotechnology, cosmetics and other fields. Recombinant humanized collagen can be used as a biological material in tissue repair and regenerative medicine, including muscles, bones, soft tissues, etc. In addition, it can also be used as a drug carrier for sustained-release drugs, such as heparin, thiazolidinone, etc., to improve the stability and bioavailability of the drug. At the same time, it can also be used to produce medical devices and medical materials such as artificial skin and artificial cornea. Recombinant humanized collagen can be used in cell culture, gene transfection, vaccine production and other aspects. It can act as a scaffold or matrix in cell culture and gene transfection, improve cell adhesion and proliferation, and promote the development of tissue engineering and stem cell research. In terms of vaccine production, recombinant humanized collagen can be used as a vaccine carrier to improve the immunogenicity and efficacy of the vaccine. Recombinant humanized collagen can be used as an ingredient for efficient anti-wrinkle, moisturizing and skin repair, and is widely used in skin care products, makeup and other products. Recombinant humanized collagen has the same amino acid sequence and tertiary structure as natural collagen, which can act directly on the skin, promote the regeneration and repair of skin cells, and improve the elasticity and gloss of the skin.The Medical Device Standard Management Center of the State Food and Drug Administration issued an interpretation of the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", which divides recombinant humanized collagen into two types, type A and type B based on whether it contains non-human collagen amino acid sequences. Type A refers to materials that do not contain non-human collagen amino acid sequences, including full-length amino acid sequences encoded by human collagen specific type genes (without triple helical structure), or partial amino acid sequence fragments encoded by human collagen specific type genes, or a combination of human collagen functional fragments (the amino acid sequences do not contain non-human collagen amino acid sequences such as linking amino acids and tag amino acids). Type B refers to the material that adds non-human collagen amino acid sequences such as amino acids and tag amino acids based on the combination of human collagen functional fragments.
Compared with animal-derived collagen, recombinant collagen has a series of obvious advantages, including higher biological activity and biocompatibility, lower immunogenicity, lower risk of missed pathogens, better water solubility, non-cytotoxicity, and can be further processed and optimized. In addition, the denaturing temperature of recombinant collagen exceeds 72°C, which is much higher than 40°C for animal-derived collagen, which makes it more stable during transportation and storage. Therefore, as a safer material, recombinant collagen is more suitable for beauty and health products. With the advancement of the industry and the development of technology, its popularity and market penetration are gradually increasing. According to the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", recombinant collagen is divided into three main categories: recombinant human collagen, recombinant humanized collagen and recombinant collagen. The core differences in these three types of recombinant collagen are reflected in the construction of expression systems, host selection, protein expression, etc. As the homologous and similarity of gene sequences increases, the expression efficiency and biological activity function of collagen vectors will also be improved accordingly.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Humanized Collagen Industry Forecast” looks at past sales and reviews total world Recombinant Humanized Collagen sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Humanized Collagen sales for 2025 through 2031. With Recombinant Humanized Collagen sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Humanized Collagen industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Humanized Collagen landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Humanized Collagen portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Humanized Collagen market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Humanized Collagen and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Humanized Collagen.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Humanized Collagen market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Type A
Type B
Segmentation by Application:
Medicine
Biotechnology
Cosmetics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Giant Biogene
Shanxi Jinbo Bio-Pharmaceutical
Jiangsu JLand Biotech
Jiangsu Chuangjian Medical Technology
Evonik
ProColl
CollPlant
Creative BioMart
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Humanized Collagen market?
What factors are driving Recombinant Humanized Collagen market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Humanized Collagen market opportunities vary by end market size?
How does Recombinant Humanized Collagen break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant humanized collagen refers to the introduction of collagen sequences encoded by human genes into cells for expression and production through gene recombination technology to obtain proteins with the same or similar structural and biological characteristics as natural collagen. Recombinant humanized collagen has many advantages, such as controllable production process, high purity, non-infectiousness, etc. It has a wide range of application prospects in medicine, biotechnology, cosmetics and other fields. Recombinant humanized collagen can be used as a biological material in tissue repair and regenerative medicine, including muscles, bones, soft tissues, etc. In addition, it can also be used as a drug carrier for sustained-release drugs, such as heparin, thiazolidinone, etc., to improve the stability and bioavailability of the drug. At the same time, it can also be used to produce medical devices and medical materials such as artificial skin and artificial cornea. Recombinant humanized collagen can be used in cell culture, gene transfection, vaccine production and other aspects. It can act as a scaffold or matrix in cell culture and gene transfection, improve cell adhesion and proliferation, and promote the development of tissue engineering and stem cell research. In terms of vaccine production, recombinant humanized collagen can be used as a vaccine carrier to improve the immunogenicity and efficacy of the vaccine. Recombinant humanized collagen can be used as an ingredient for efficient anti-wrinkle, moisturizing and skin repair, and is widely used in skin care products, makeup and other products. Recombinant humanized collagen has the same amino acid sequence and tertiary structure as natural collagen, which can act directly on the skin, promote the regeneration and repair of skin cells, and improve the elasticity and gloss of the skin.The Medical Device Standard Management Center of the State Food and Drug Administration issued an interpretation of the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", which divides recombinant humanized collagen into two types, type A and type B based on whether it contains non-human collagen amino acid sequences. Type A refers to materials that do not contain non-human collagen amino acid sequences, including full-length amino acid sequences encoded by human collagen specific type genes (without triple helical structure), or partial amino acid sequence fragments encoded by human collagen specific type genes, or a combination of human collagen functional fragments (the amino acid sequences do not contain non-human collagen amino acid sequences such as linking amino acids and tag amino acids). Type B refers to the material that adds non-human collagen amino acid sequences such as amino acids and tag amino acids based on the combination of human collagen functional fragments.
Compared with animal-derived collagen, recombinant collagen has a series of obvious advantages, including higher biological activity and biocompatibility, lower immunogenicity, lower risk of missed pathogens, better water solubility, non-cytotoxicity, and can be further processed and optimized. In addition, the denaturing temperature of recombinant collagen exceeds 72°C, which is much higher than 40°C for animal-derived collagen, which makes it more stable during transportation and storage. Therefore, as a safer material, recombinant collagen is more suitable for beauty and health products. With the advancement of the industry and the development of technology, its popularity and market penetration are gradually increasing. According to the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", recombinant collagen is divided into three main categories: recombinant human collagen, recombinant humanized collagen and recombinant collagen. The core differences in these three types of recombinant collagen are reflected in the construction of expression systems, host selection, protein expression, etc. As the homologous and similarity of gene sequences increases, the expression efficiency and biological activity function of collagen vectors will also be improved accordingly.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Humanized Collagen Industry Forecast” looks at past sales and reviews total world Recombinant Humanized Collagen sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Humanized Collagen sales for 2025 through 2031. With Recombinant Humanized Collagen sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Humanized Collagen industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Humanized Collagen landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Humanized Collagen portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Humanized Collagen market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Humanized Collagen and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Humanized Collagen.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Humanized Collagen market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Type A
Type B
Segmentation by Application:
Medicine
Biotechnology
Cosmetics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Giant Biogene
Shanxi Jinbo Bio-Pharmaceutical
Jiangsu JLand Biotech
Jiangsu Chuangjian Medical Technology
Evonik
ProColl
CollPlant
Creative BioMart
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Humanized Collagen market?
What factors are driving Recombinant Humanized Collagen market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Humanized Collagen market opportunities vary by end market size?
How does Recombinant Humanized Collagen break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
105 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Recombinant Humanized Collagen by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Recombinant Humanized Collagen by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
